9 METERS BIOPHARMA, INC.

2022 Q4 Form 10-Q Financial Statement

#000155198622000114 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.65M $15.86M
YoY Change -73.09% -70.41%
Cash & Equivalents $12.60M $15.90M
Short-Term Investments
Other Short-Term Assets $20.37M $2.593M
YoY Change 580.88% -9.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $33.02M $18.45M
YoY Change -33.94% -67.33%
LONG-TERM ASSETS
Property, Plant & Equipment $10.41K $12.95K
YoY Change -35.3% -20.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.280K $5.580K
YoY Change 30.47% 0.0%
Total Long-Term Assets $130.0K $23.68M
YoY Change -30.96% 11672.11%
TOTAL ASSETS
Total Short-Term Assets $33.02M $18.45M
Total Long-Term Assets $130.0K $23.68M
Total Assets $33.15M $42.14M
YoY Change -33.93% -25.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.053M $1.438M
YoY Change 107.57% 9.21%
Accrued Expenses $4.380M $6.774M
YoY Change -26.61% 14.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $19.62M $2.646M
YoY Change
Total Short-Term Liabilities $30.70M $12.86M
YoY Change 262.96% 76.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $15.74M
YoY Change
Other Long-Term Liabilities $51.40K $67.53K
YoY Change -54.57% -47.02%
Total Long-Term Liabilities $51.40K $15.74M
YoY Change -54.57% 12252.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.70M $12.86M
Total Long-Term Liabilities $51.40K $15.74M
Total Liabilities $30.75M $28.67M
YoY Change 258.77% 287.05%
SHAREHOLDERS EQUITY
Retained Earnings -$212.6M -$200.7M
YoY Change 25.92% 25.99%
Common Stock $1.304K $1.296K
YoY Change -94.95% -94.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.401M $13.46M
YoY Change
Total Liabilities & Shareholders Equity $33.15M $42.14M
YoY Change -33.93% -25.66%

Cashflow Statement

Concept 2022 Q4 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001551986
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37797
dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
275-1933
dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
dei Trading Symbol
TradingSymbol
NMTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12955481 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15860966 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46993285 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2592633 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2991948 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
18453599 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
49985233 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
23536576 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12953 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16094 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
126500 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166618 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 usd
CY2022Q3 us-gaap Assets
Assets
42135208 usd
CY2021Q4 us-gaap Assets
Assets
50173525 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1437685 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434452 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6774205 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2646000 usd
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1945000 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59930 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54796 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12862820 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8457070 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67530 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113142 usd
CY2022Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
15744057 usd
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2022Q3 us-gaap Liabilities
Liabilities
28674407 usd
CY2021Q4 us-gaap Liabilities
Liabilities
8570212 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12955481 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12955481 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12911771 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12911771 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1296 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1291 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
214136684 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210442689 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200677179 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168840667 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13460801 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42135208 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50173525 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6298501 usd
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6049444 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22213456 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14947036 usd
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5103753 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5103753 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2417484 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2386461 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9062199 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7146432 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8715985 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
13539658 usd
us-gaap Operating Expenses
OperatingExpenses
31275655 usd
us-gaap Operating Expenses
OperatingExpenses
27197221 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8715985 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13539658 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31275655 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27197221 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
131655 usd
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
1397 usd
us-gaap Interest Income Other
InterestIncomeOther
209788 usd
us-gaap Interest Income Other
InterestIncomeOther
12989 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
847341 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
1970 usd
us-gaap Interest Expense
InterestExpense
847645 usd
us-gaap Interest Expense
InterestExpense
47188 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
77000 usd
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
77000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-638686 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-573 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-560857 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27199 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9354671 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13540231 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31836512 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27224420 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9354671 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13540231 usd
us-gaap Net Income Loss
NetIncomeLoss
-31836512 usd
us-gaap Net Income Loss
NetIncomeLoss
-27224420 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.28
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12955481 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12955481 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12714238 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12714238 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12939310 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12939310 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11926510 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11926510 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30941574 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1774000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11130102 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
22085472 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
730000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9354671 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13460801 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
422000 usd
CY2021Q1 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
6857028 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75903 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2901123 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
937000 usd
CY2021Q2 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
668439 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120739 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8253110 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59137910 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2718587 usd
CY2021Q3 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
399967 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30064 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
525000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13540231 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
49271297 usd
us-gaap Net Income Loss
NetIncomeLoss
-31836512 usd
us-gaap Net Income Loss
NetIncomeLoss
-27224420 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3194000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1884000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
500351 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 usd
us-gaap Depreciation
Depreciation
5983 usd
us-gaap Depreciation
Depreciation
4657 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-77000 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 usd
nmtr Non Cash Milestone Fees
NonCashMilestoneFees
500000 usd
nmtr Non Cash Milestone Fees
NonCashMilestoneFees
0 usd
nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
0 usd
nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
2610588 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-399315 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1869438 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-996767 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-63567 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
806023 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3114077 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27504607 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21507608 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9848 usd
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
0 usd
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
-75000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2493165 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2842 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2428013 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
21000000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1088294 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
226706 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34500000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2901123 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7925434 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19911706 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39692818 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7595743 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15757197 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46993285 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39397542 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53608585 usd
us-gaap Interest Paid Net
InterestPaidNet
346990 usd
us-gaap Interest Paid Net
InterestPaidNet
569 usd
nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
2022000 usd
nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
0 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15860966 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53608585 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
23536576 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39397542 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53608585 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2300000 shares
CY2020Q4 nmtr Sale Of Stock Shelf Registration Maximum Equity Offering Price
SaleOfStockShelfRegistrationMaximumEquityOfferingPrice
200000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include fair value measurements, expected term of the convertible note, accrued expenses, share-based compensation, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7400000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7400000 shares
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654688 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1633295 usd
CY2022Q3 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
5016241 usd
CY2021Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4228048 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
103276 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106479 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6774205 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 usd
CY2022Q3 us-gaap Share Price
SharePrice
4.87
CY2022Q3 us-gaap Share Price
SharePrice
4.30
CY2022Q3 nmtr Derivative Liability Term
DerivativeLiabilityTerm
P3Y
nmtr Derivative Liability Term
DerivativeLiabilityTerm
P2Y9M18D
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0 usd
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1945000 usd
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1945000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
100000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
7000 usd
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7383102 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2315298 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15900000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
23500000 usd
CY2021Q3 nmtr Asset Acquisition Equity Interest Issued Or Issuable Number Of Shares
AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares
120861 shares
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5292000 usd
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10584000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6174000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
22050000 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3659943 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2646000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15744057 usd
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 licenseagreement
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 usd
nmtr Accrued Milestone Fees
AccruedMilestoneFees
500000 usd
nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2021Q3 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2022Q3 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 usd
CY2022Q3 nmtr Capital Stock Shares Authorized
CapitalStockSharesAuthorized
560000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12955481 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12911771 shares
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10406505 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2470883 shares
CY2022Q3 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
3 equity-basedincentiveplan
nmtr Share Based Compensation Arrangement By Share Based Payment Award Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTerm
P10Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
730000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
525000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3194000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1884000 usd
nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
nmtr Severance Provisions Termination Or Resignation Annual Base Salary Period
SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod
P18M
us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2021Q3 us-gaap Severance Costs1
SeveranceCosts1
0 usd
us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2022Q3 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
100000 usd
CY2021Q4 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
400000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Lessee Operating Lease Base Rent Payment
LesseeOperatingLeaseBaseRentPayment
6000 usd
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 usd
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 usd
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 usd
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
54000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
54000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
54000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
54000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
100000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
144000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16540 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
144000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16540 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
127460 usd

Files In Submission

Name View Source Status
0001551986-22-000114-index-headers.html Edgar Link pending
0001551986-22-000114-index.html Edgar Link pending
0001551986-22-000114.txt Edgar Link pending
0001551986-22-000114-xbrl.zip Edgar Link pending
nmtr-20220930_lab.xml Edgar Link unprocessable
ex-101amendmenttoconvertib.htm Edgar Link pending
ex311q32022.htm Edgar Link pending
ex312q32022.htm Edgar Link pending
ex321q32022.htm Edgar Link pending
ex322q32022.htm Edgar Link pending
exhibit31articlesofincorpa.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image1.jpg Edgar Link pending
image2.jpg Edgar Link pending
image3.jpg Edgar Link pending
image4.jpg Edgar Link pending
image5.jpg Edgar Link pending
image6.jpg Edgar Link pending
image7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20220930.htm Edgar Link pending
nmtr-20220930.xsd Edgar Link pending
nmtr-20220930_g1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
nmtr-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nmtr-20220930_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nmtr-20220930_def.xml Edgar Link unprocessable
nmtr-20220930_pre.xml Edgar Link unprocessable